<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Systemic treatment for metastatic or advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>(mCRC)has remarkably progressed during recent years </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> previously untreated mCRC patients at our institution between November, 2007 and June, 2010 were retrospectively evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>Of 72 patients, 39 were treated with chemotherapy alone, and 33 were treated with chemotherapy plus bevacizumab(BV) </plain></SENT>
<SENT sid="3" pm="."><plain>The median progression-free survival(mPFS)was 329 days in the group given chemotherapy plus BV, compared with 209 days in the group given chemotherapy alone(p=0 </plain></SENT>
<SENT sid="4" pm="."><plain>0189) </plain></SENT>
<SENT sid="5" pm="."><plain>In sub-group analysis of those treated with chemotherapy plus BV, mPFS between 70 y/o&lt;and&lt;70 y/o was not different(368 vs 306 days, respectively; p=0 </plain></SENT>
<SENT sid="6" pm="."><plain>7872) </plain></SENT>
<SENT sid="7" pm="."><plain>The relative dose intensity of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>(L-OHP)was 80% in the group with FOLFOX+BV(n=15), and 92% with XELOX+BV(n=8) </plain></SENT>
<SENT sid="8" pm="."><plain>Chemotherapy with BV for previously untreated mCRC was well tolerated and effective </plain></SENT>
</text></document>